Prediction of ventricular arrhythmia events in ischemic heart disease patients with implantable cardioverter-defibrillators.

Abstract

The aim of the study was to exam the prediction of ventricular arrhythmia events in ischemic heart disease patients with implantable cardioverter-defibrillators (ICD). A total of 123 consecutive patients confirmed ischemia heart disease with ICD were examined. After device implantation, the occurrence of appropriate ICD therapy was noted. Patients were divided into two groups according to the ventricular arrhythmia occurrence. Patients with ventricular arrhythmia occurrence had a significantly great incidence of atrial fibrillation history compare to the no-ventricular arrhythmia occurrence group (8 vs. 39%, P = 0.02). The level of high-sensitive C-reactive protein (hsCRP) baseline was also significantly higher in the ventricular arrhythmia group than in the no ventricular arrhythmia (3.78 ± 1.1 vs. 0.94 ± 0.7, P < 0.01). The taking of β blocker is not common in ventricular arrhythmia group patients than no ventricular arrhythmia group (5 vs. 29%, P = 0.03). By univariate comparison, male sex, the history of atrial fibrillation, and a high level of hsCRP were significant predictors for ventricular arrhythmia occurrence. By multivariate analysis, the atrial fibrillation burden, and had a high level of hsCRP were significant for incidence of ventricular arrhythmia occurrence in ischemic heart disease patients. β-block were more likely to be free from ventricular arrhythmia occurrence. The high level of hsCRP, and the atrial fibrillation burden were strong predictor of ventricular arrhythmia occurrence in secondary prevention ICD recipients with ischemic heart disease. Taking β-blockers was free from ventricular arrhythmia occurrence.